Glenmark Life Sciences Ltd. IPO

IPO Issue Details

Issue Price / Price Band₹720 per share (Fixed Price)

Face Value₹2 Per Share

Lot Size20 Shares per Lot

Total Issue Size2,10,22,222 shares (aggregating up to ₹1,513.60 Cr)

Issue TypeBookbuilding IPO

Sale Type / CategoryFresh Capital-cum-Offer for Sale

Exchange / PlatformNSE & BSE

IPO TypeMainboard

Subscription OpenTue, 27 Jul 2021

Subscription CloseThu, 29 Jul 2021

Anchor AllotmentMon, 26 Jul 2021

Basis of AllotmentTue, 03 Aug 2021

Initiation of RefundsWed, 04 Aug 2021

Credit of Shares to DematThu, 05 Aug 2021

Listing DateFri, 06 Aug 2021

UPI Mandate Deadline2021-07-29

Application & Investment Details

Retail — Min (1 Lots)₹14,400 — 20 shares

Retail — Max (13 Lots)₹187,200 (13 Lots)

HNI — Min (14 Lots)₹2,01,600 — 280 shares

Pre-IPO Promoter Holding10,78,04,950 shares

Post-IPO Promoter Holding12,25,27,172 shares

Fresh Issue Shares1,47,22,222 shares (aggregating up to ₹1,060.00 Cr)

Offer for Sale Shares63,00,000 shares of ₹2 (aggregating up to ₹453.60 Cr)

About Glenmark Life Sciences Ltd.

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.Competitive strengthsLeading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.Export products in Europe, Latin America, North America, Japan, and the rest of the world.Strong relationship with leading global generic companies.Proven track record of strong financial performance.High-quality product manufacturing with R&D infrastructure.

Objects of the Issue

Glenmark Life Sciences Ltd. proposes to utilise the net proceeds from the Issue for the following objects:

1 Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018

800.00

2 Funding the capital expenditure requirements

152.76

3 General corporate purposes

57.68

Shareholding & Lock-in

Pre-IPO Promoter Holding 10,78,04,950 shares

Post-IPO Promoter Holding 12,25,27,172 shares

Lock-in Period (30%)September 2, 2021

Lock-in Period (50%)November 1, 2021

Check AllotmentCheck Status →

₹720.00

INR · BSE

Fetching live data…

VS Issue Price

—

OPEN

—

HIGH

—

LOW

—

MKT CAP

—

P/E

—

52W HIGH

—

52W LOW

—

VOLUME

—

DIVIDEND

—

DIV YIELD

—

Loading chart…

Chart Not Available

Glenmark Life Sciences Ltd. is not yet listed on Yahoo Finance or has a different ticker symbol.
Try again after listing stabilises (2-3 trading days).

Issue ₹720.00 Live Price

Quick Facts

GMP Signal ⚪ No GMP

StatusListed

Issue Price₹720

GMPNIL

Est. Listing₹720

Lot Size20 shares

Min Amount₹28,800

Listing Date06 Aug 2021

Disclaimer: GMP is unofficial and unregulated. It does not guarantee actual listing price.

Listing Performance

Issue Price₹720

Listing Date06 Aug 2021

Listing Price—

Listing Gain/Loss—%

52-Week High—

52-Week Low—

Issue Structure & Reservation

Category	Shares Offered	% Issue	Amount (₹ Cr)*	Subscription
TOTAL	21,022,222	100.00%	₹1,513.60 Cr	—

* Based on ₹720.00 (upper price band)

Lot Size & Investment Details

Lot Size

Issue Price

₹720.00

Per Share

Min Investment

₹14,400

1 Lot

Category	Lots	Shares	Amount (₹)
Retail (Min)	1	20	₹14,400
Retail (Max)	13	260	₹187,200
sNII (Min)	14	280	₹201,600
bNII (Min)	70	1,400	₹1,008,000

Company Financials — Restated Consolidated (Amount in Crore)

Particulars	31-Mar-21	31-Mar-20	31-Mar-19
Revenue from Operations	1885.98	1549.30	886.87
EBITDA	N/A	N/A	N/A
Profit After Tax (PAT)	351.58	313.10	195.59
Net Worth	N/A	N/A	N/A
Total Assets	1997.08	1725.60	1475.40
Reserves & Surplus	N/A	N/A	N/A
Total Borrowings	N/A	N/A	N/A

Key Ratios & Valuation

Issue Price ₹720

Face Value ₹2 Per Share

P/BV N/A

RoE N/A

RoCE N/A

RoNW N/A

PAT Margin (%) N/A

EBITDA Margin (%) N/A

Debt / Equity N/A

Company Details

Company

Glenmark Life Sciences Ltd.

Exchange

NSE & BSE

IPO Type

Mainboard IPO

Issue Type

Bookbuilding IPO

Face Value

₹2 Per Share

Script Code

N/A

Address

Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213, Mohol, Maharashtra

Phone

+91 2189 234456/ +91 2189

complianceofficer@glenmarklifesciences.com

Website

http://www.glenmarklifesciences.com/

IPO Registrar

Kfin Technologies Ltd.

04067162222, 04079611000

glenmark.ipo@kfintech.com

https://ipostatus.kfintech.com/

Check Allotment Status

Book Running Lead Managers

BOFA Securities India Ltd.